Overview
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
Status:
Completed
Completed
Trial end date:
2020-05-20
2020-05-20
Target enrollment:
0
0
Participant gender:
All
All
Summary
This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents with type 2 diabetes.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novo Nordisk A/STreatments:
Liraglutide
Metformin
Criteria
Inclusion Criteria: - Children and adolescents between the ages of 10-16 years. Subjectscannot turn 17 years and 11 months before the end of treatment (52 weeks) - Diagnosis of
type 2 diabetes mellitus and treated for at least 30 days with: diet and exercise alone,
diet and exercise in combination with metformin monotherapy, diet and exercise in
combination with metformin and a stable (Stable is defined as basal insulin adjustments up
to 15%) dose of basal insulin, diet and exercise in combination with a stable (Stable is
defined as basal insulin adjustments up to 15%) dose of basal insulin - HbA1c: 7.0-11%
(inclusive) if diet and exercise treated or 6.5-11% (inclusive) if treated with metformin
as monotherapy, basal insulin as monotherapy or metformin and basal insulin in combination
- Body mass index (BMI) above 85% percentile of the general age and gender matched
population Exclusion Criteria: - Type 1 diabetes - Maturity onset diabetes of the young
(MODY) - Use of any antidiabetic agent other than metformin and/or basal insulin within 90
days prior to screening - Recurrent severe hypoglycaemia or hypoglycaemic unawareness as
judged by the investigator - History of chronic pancreatitis or idiopathic acute
pancreatitis - Any clinically significant disorder, except for conditions associated with
type 2 diabetes history which in the investigator's opinion could interfere with results of
the trial - Uncontrolled hypertension, treated or untreated above 99th percentile for age
and gender in children - Known or suspected abuse of alcohol or drugs/narcotics